Pharmacogenomics in the Management of Pulmonary Arterial Hypertension: Current Perspectives.

ABSTRACT: Pulmonary arterial hypertension (PAH) is a rare disease with heterogeneous causes that can lead to right ventricular (RV) failure and death if left untreated. There are currently 10 medications representative of five unique pharmacologic classes that are approved for treatment. These have led to significant improvements in overall clinical outcome. However, substantial variability in dosing requirements and treatment response is evident, leading to suboptimal outcome for many patients. Furthermore, dosing is empiric and iterative and can lead to delays in meeting treatment goals and burdensome adverse effects. Pharmacogenomic (PGx) associations have been reported with certain PAH medications, such as treprostinil and bosentan, and can explain some of the variability in response. Relevant g

SUBMITTER: Coons JC 

PROVIDER: S-EPMC10349598 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature